DaVita (DVA)
(Delayed Data from NYSE)
$137.95 USD
+1.89 (1.39%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $137.99 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DVA 137.95 +1.89(1.39%)
Will DVA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DVA
DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts
DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?
DVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Patterson Companies (PDCO) Aims to Streamline Patient Experience
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results
Alcon (ALC) Rides on Innovation, Balanced Segmental Sales
Other News for DVA
Financial Crime Weekly: DaVita Agrees To Pay $34.5M For Kickbacks, Hospice Provider Doles Out $19.4M For False Claims
DaVita Inc. Schedules 2nd Quarter 2024 Investor Conference Call
FHLC: Healthcare Dashboard For July
DaVita (DVA) Gets a Hold from Barclays
Long-term beneficiaries of AI, according to Goldman Sachs